- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Enzymatica AB: Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 October 2026 | 113 | GlobeNewswire (Europe) | On 22 October 2026, the shareholders of Enzymatica AB (publ) (the "Company") held an Extraordinary General Meeting. The following principal resolutions were adopted at the Meeting.
Resolution on the... ► Artikel lesen | |
| Mi | Enzymatica AB: Enzymatica enters MENA - signs distribution agreement for ColdZyme in Jordan and Iraq | 105 | GlobeNewswire (Europe) | Lund, Sweden, [DATE] 2026. Enzymatica AB (publ) has signed a long-term exclusive distribution agreement with MedonyX, an MMDS-backed company, for the registration, marketing, sale and distribution of... ► Artikel lesen | |
| 16.10. | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | 316 | GlobeNewswire (Europe) | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| 27.08. | Enzymatica AB: Enzymatica strengthens its management team with commercial and scientific expertise | 419 | GlobeNewswire (Europe) | Enzymatica Enzymatica is strengthening its management team with the addition of Nordic Marketing and Sales Director Joakim Tingström Nordin and Chief Scientist and Head of Production Iceland Bjarki... ► Artikel lesen | |
| 16.07. | Enzymatica AB: Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization | 305 | GlobeNewswire (Europe) | Second quarter· Net sales reached SEK 7,1 (8.3) million.· The operating result totaled SEK -12.6 (-14.9) million.· Earnings per share, basic and diluted, were SEK -0.05 (-0.06).· Cash flow from operating... ► Artikel lesen | |
| 24.06. | Enzymatica AB: The evidence base for ColdZyme remains unchanged - PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme | 231 | GlobeNewswire (Europe) | Enzymatica AB (publ) notes that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the company's placebo-controlled Berlin II study from 2023. The notice... ► Artikel lesen | |
| 09.06. | Enzymatica AB: Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme's continued growth in the Nordics | 697 | GlobeNewswire (Europe) | Enzymatica has appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme's commercial development... ► Artikel lesen | |
| 07.05. | Enzymatica AB: Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026 | 352 | GlobeNewswire (Europe) | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Enzymatica AB (publ) held its annual... ► Artikel lesen | |
| ENZYMATICA Aktie jetzt für 0€ handeln | |||||
| 28.04. | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | 1.376 | GlobeNewswire (Europe) | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| 31.03. | Enzymatica AB: Enzymatica and STADA sign partnership agreement for Germany and Austria | 1.020 | GlobeNewswire (Europe) | Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica's ColdZyme® technology in oral spray form in Germany and Austria
• The partnership combines... ► Artikel lesen | |
| 18.02. | Enzymatica AB: Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion | 636 | PR Newswire | LUND, Sweden, Feb. 18, 2026 /PRNewswire/ --
Fourth quarterJanuary-December
Net sales reached SEK 18.3 (17.2) millionThe operating result totaled SEK -10.2 (-13.7) million.Earnings... ► Artikel lesen | |
| 11.12.25 | Enzymatica AB: Enzymatica appoints Acting CFO during transition period | 280 | GlobeNewswire (Europe) | Enzymatica today announces the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the... ► Artikel lesen | |
| 20.11.25 | Enzymatica AB: Enzymatica enters partnership with the UK Sports Institute to support athlete health and performance | 445 | GlobeNewswire (Europe) | ColdZyme, the mouth spray developed by Enzymatica AB, has entered into a new partnership with the UK Sports Institute (UKSI) to support the institute's work in promoting athlete health and wellbeing.
The... ► Artikel lesen | |
| 30.10.25 | Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion | 436 | PR Newswire | LUND, Sweden, Oct. 30, 2025 /PRNewswire/ --
Third quarter
January-September
... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,120 | -0,20 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen | |
| NOVO NORDISK | 35,300 | +0,44 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| PFIZER | 27,095 | -0,06 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| GILEAD SCIENCES | 139,68 | -0,34 % | BioNTech SE: BioNTech treibt klinische Phase-3-Studie zu Pumitamig mit Gileads gegen TROP2-gerichtetem Antikörper-Wirkstoff-Konjugat Sacituzumab Govitecan bei Dreifach-Negativem Brustkrebs voran | BioNTech schließt eine klinische Studienkollaboration mit Gilead Sciences ab; Ziel ist es, die Behandlungsergebnisse für Patientinnen und Patienten mit dreifach-negativem Brustkrebs zu verbessern, deren... ► Artikel lesen | |
| SANOFI | 74,40 | -0,32 % | RBC stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Sanofi vor Zahlen für das dritte Quartal von 80 auf 75 Euro gesenkt und die Einstufung auf "Sector Perform" belassen. Die Stärke... ► Artikel lesen | |
| GSK | 22,840 | 0,00 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK nach Studiendaten für das Krebs-Konjugat Risvutatug Rezetecan mit einem Kursziel von 2500 Pence auf "Buy" belassen.... ► Artikel lesen | |
| ABBVIE | 253,20 | -0,32 % | AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa | In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1
... ► Artikel lesen | |
| ASTRAZENECA | 152,75 | -0,68 % | BERENBERG stuft ASTRAZENECA auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Astrazeneca nach einer Investorenveranstaltung zum Thema 'Seltene Krankheiten' auf "Buy" mit einem Kursziel von 15000 Pence... ► Artikel lesen | |
| INNOCAN PHARMA | 1,175 | 0,00 % | Innocan Pharma startet online - was Anleger wissen müssen | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| VIATRIS | 16,620 | +0,90 % | FDA Approves Viatris' RYZUMVI For Presbyopia Treatment | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.RYZUMVI... ► Artikel lesen | |
| SINOPHARM | 1,745 | +0,55 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 | ||
| HALEON | 4,595 | 0,00 % | Haleon Canada: Haleon Launches 'Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto | ||
| LIGAND PHARMACEUTICALS | 274,00 | 0,00 % | Ligand Pharmaceuticals: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million | JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,800 | 0,00 % | Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026 |
ENZYMATICA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,34 % bei einem Aktienkurs von 0,145 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENZYMATICA AB finden Sie auf Wallstreet Online.